Domingo, 30 de agosto de 2009

La jornada del domingo en el ESC Congress Barcelona'09 ofreció numerosas sesiones científicas de gran interés. Entre ellas, destacaron la presentación de los estudios PLATO y RE-LY.

Título	Ponente	Tema
Is elevated resting heart rate an independent predictor of cardiovascular disease? A report from the National FINRISK Study.	M T Cooney (Dublin, IE)	Epidemiology & prevention
Resting heart rate remains a risk factor for CardioVascular (CV) and non-CardioVascular (non-CV) mortality in healthy subjects after adjusting for inflammatory markers. The Copenhagen city heart study.	M T Jensen (Copenhagen, DK)	Epidemiology & prevention
Increased exercise capacity is associated with lower mortality risk in men 70 years and older.	P Kokkinos (Washington, US)	Epidemiology & prevention
Adipokines and coronary heart disease - results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.	M Karakas (Ulm, DE)	Epidemiology & prevention
Respective contribution of carotid intima-media thickness and plaques to incident coronary heart disease in community-dwelling elderly. The three-city study.	M Plichart (Paris, FR)	Epidemiology & prevention
Uric acid: an underestimated cardiovascular risk factor.	G Levantesi (Vasto, IT)	Epidemiology & prevention
Population approach in coronary prevention: the method of choice. Pro.	T Jorgensen (Glostrup, DK)	Epidemiology & prevention
Population approach in coronary prevention: the method of choice: Contra.	G De Backer (Ghent, BE)	Epidemiology & prevention
Population versus high-risk approach in cardiovascular prevention. Conclusion.	C M van Duijn (Rotterdam, NL)	Epidemiology & prevention
Genetic screening of coronary predisposition is coming to clinical practice: Pro.	H Schunkert (Lubeck, DE)	Epidemiology & prevention
Genetic screening of coronary predisposition is coming to clinical practice: Contra.	C M van Duijn (Rotterdam, NL)	Epidemiology & prevention
Genetic screening of coronary predisposition is coming to clinical practice: Pro.	H Schunkert (Lubeck, DE)	Epidemiology & prevention
Genetic screening of coronary predisposition is coming to clinical practice: Contra.	C M van Duijn (Rotterdam, NL)	Epidemiology & prevention
Population versus high-risk approach in cardiovascular prevention: Conclusion.	C M van Duijn (Rotterdam, NL)	Epidemiology & prevention
Randomised controlled trial of low dose aspirin in the prevention of cardiovascular events and death in subjects with asymptomatic atherosclerosis.: Discussant.	C Patrono (Rome, IT)	Epidemiology & prevention
A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: Results of the CURRENT OASIS 7 Trial.	S R Mehta (Hamilton, CA)	Ischaemia / ACS / infarction
CURRENT OASIS 7: Discussant.	F Van de Werf (Leuven, BE)	Ischaemia / ACS / infarction
Comparison of Ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: results of the PLATelet inhibition and patient Outcomes (PLATO) trial.	L C Wallentin (Uppsala, SE)	Ischaemia / ACS / infarction
PLATO: Discussant.	S D Kristensen (Aarhus N, DK)	Ischaemia / ACS / infarction
A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke.	S J Connolly (Hamilton, CA)	Arrhythmias / Pacing / Resynchronisation
A randomized trial of dabigatran, a oral direct thrombin inhibitor, compared to warfarin in 18,113 patients with atrial fibrillation at high risk of stroke.: Discussant.	A J Camm (London, GB)	Arrhythmias / Pacing / Resynchronisation
Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42.	M Sabatine (Boston, US)	Ischaemia / ACS / infarction
SEPIA-ACS1 TIMI 42: Discussant.	H D White (Auckland, NZ)	Ischaemia / ACS / infarction
Genetics of inflammation and atherosclerosis.	H Schunkert (Lubeck, DE)	Vascular biology
Inflammatory biomarkers and therapeutic implications.	A C Newby (Bristol, UK)	Vascular biology
A patient with persisting fever.	A Vahanian (Paris, FR)	Valvular disease
Endocarditis: coping with the Guidelines: What do the guidelines tell us?	A Vahanian (Paris, FR)	Valvular disease
A deteriorating patient despite appropriate initial treatment choices.	J L Vachiery (Brussels, BE)	Pulmonary circulation
A young lady who is improving but not enough.	N Galie (Bologna, IT)	Pulmonary circulation
What do the Guidelines say?	N Galie (Bologna, IT)	Pulmonary circulation
Treating dyslipidemia. How aggressive should we be? Case 1.	U Landmesser (Zurich, CH)	Epidemiology & prevention
Treating dyslipidemia. How aggressive should we be? Case 2.	J E Deanfield (London, GB)	Epidemiology & prevention
What do the Guidelines say?	I M Graham (Dublin, IE)	Epidemiology & prevention
ESC Guidelines on the prevention, diagnosis and treatment of infective endocarditis.	G Habib (Marseille, FR)	Valvular disease
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.	N Galie (Bologna, IT)	Pulmonary circulation
ESC Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery.	D Poldermans (Rotterdam, NL)	Peripheral circulation/Stroke
ESC Guidelines for the management of syncope.	A Moya I Mitjans (Barcelona, ES)	Arrhythmias / Pacing / Resynchronisation
Risk stratification and diagnostic strategy in patients with syncope.	A Moya I Mitjans (Barcelona, ES)	Arrhythmias / Pacing / Resynchronisation
Syncope unit: utopia or a necessity.	M Brignole (Lavagna, IT)	Arrhythmias / Pacing / Resynchronisation
Specific aspects of syncope in the elderly: a growing problem.	A Ungar (Firenze, IT)	Arrhythmias / Pacing / Resynchronisation
Future directions in diagnosis and management of syncope.	D G Benditt (Minneapolis, US)	Arrhythmias / Pacing / Resynchronisation
Defining and managing advanced heart failure.	A Fucili (Ferrara, IT)	Heart failure / LV dysfunction
Lessons from the INTERMACS registry.	K Dickstein (Stavanger, NO)	Heart failure / LV dysfunction
Surgical interventions and short-term devices.	A Pitsis (Thessaloniki, GR)	Heart failure / LV dysfunction
Long-term devices and the artificial heart.	S Westaby (Oxford, GB)	Heart failure / LV dysfunction
Circulating endothelial progenitor cells and acute myocardial infarction.	S Dimmeler (Frankfurt, DE)	Cardiovascular system (patho)physiology
Pretreatment of stem cells and recipient tissues.	K Lunde (Oslo, NO)	Cardiovascular system (patho)physiology
Cardiac stem cells.	D Torella (Catanzaro, IT)	Cardiovascular system (patho)physiology
C-reactive protein and other plasma markers, of incremental value in risk prediction.	W Koenig (Ulm, DE)	Cardiac cellular biology
The endothelial surface layer/glycocalyx: an emerging player in vascular health and disease.	H Vink (Maastricht, NL)	Cardiac cellular biology
The impact of early diet and interventions on the vasculature in animal models.	C Torrens (Southampton, GB)	Cardiac cellular biology
Impact of endothelial dysfunction on atherosclerosis development in childhood.	P Leeson (Oxford, GB)	Cardiac cellular biology
B-CONVINCED. Beta-blocker CONtinuation Versus INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode.	G Jondeau (Paris, FR)	Heart failure / LV dysfunction
B-CONVINCED: Discussant.	K Swedberg (Goteborg, SE)	Heart failure / LV dysfunction
BEAUTIFUL: Discussant.	M Boehm (Homburg/Saar, DE)	Pharmacology and pharmacotherapy
Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial.	A P Maggioni (Florence, IT)	Arrhythmias / Pacing / Resynchronisation
GISSI-HF: Discussant.	HJGM Crijns (Maastricht, NL)	Arrhythmias / Pacing / Resynchronisation
Heart failure events assessment in the Rosiglitazone Evaluation for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD).	M Komajda (Paris, FR)	Heart failure / LV dysfunction
Characteristics of patients enrolled in the Predictors of Response to CRT (PROSPECT) trial: comparison of subgroups according to extent of LV reverse remodeling.	RJ van Bommel (Leiden, NL)	Arrhythmias / Pacing / Resynchronisation
PROSPECT: Discussant.	C Linde (Stockholm, SE)	Arrhythmias / Pacing / Resynchronisation
Cardiac Resynchronization Therapy Induces Major Structural and Functional Reverse Remodeling In Mild Heart Failure. 24 month results of the REVERSE trial.	S Ghio (Pavia, IT)	Arrhythmias / Pacing / Resynchronisation
REVERSE: Discussant.	J G F Cleland (Kingston upon Hull, GB)	Arrhythmias / Pacing / Resynchronisation
Prehospital challenges.	P M Clemmensen (Copenhagen, DK)	Ischaemia / ACS / infarction
Evolving strategies for reperfusion therapy.	N Danchin (Paris, FR)	Ischaemia / ACS / infarction
Optimal antithrombotic therapy.	L C Wallentin (Uppsala, SE)	Ischaemia / ACS / infarction
Late-comers: which options?	A Abbate (Richmond, US)	Ischaemia / ACS / infarction

Cardiología hoy | Blog

Guías clínicas

Agenda SEC

CardioPODCAST

Cursos SEC

Másteres y Posgrados

Formación SEC 2025

CardioTV

Domingo, 30 de agosto de 2009

Actualidad

Revista Española de Cardiología

REC: Interventional Cardiology

REC: CardioClinics

Socios estratégicos